Close Menu

NEW YORK (GenomeWeb) – No longer a rumor, human germline editing with CRISPR/Cas9 is now the subject of a study published today in Protein & Cell. The results indicate that any therapeutic use of the technology in humans remains distant.

Scientists from Sun Yat-sen University in Guangzhou, China, led by Canquan Zhou and Junjiu Huang, used the CRISPR/Cas9 genome editing system in non-viable human zygotes to modify the gene that causes the hereditary blood disease beta-thalassemia.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.